ヒト培養細胞由来B型肝炎ワクチンの有用性の検討 Effectiveness of a Human Cell Culture-Derived Hepatitis B Vaccine

この論文にアクセスする

この論文をさがす

著者

    • 藤瀬 清隆 FUJISE Kiyotaka
    • 東京慈恵会医科大学附属柏病院消化器・肝臓内科 Division of Gastroenterology and Hepatology, Jikei University Kashiwa Hospital
    • 春日 葉子 KASUGA Yoko
    • 東京慈恵会医科大学附属柏病院消化器・肝臓内科 Division of Gastroenterology and Hepatology, Jikei University Kashiwa Hospital
    • 鈴木 憲治 [他] SUZUKI Kenji
    • 東京慈恵会医科大学附属柏病院消化器・肝臓内科 Division of Gastroenterology and Hepatology, Jikei University Kashiwa Hospital
    • 内藤 嘉彦 NAITO Yoshihiko
    • 東京慈恵会医科大学附属柏病院消化器・肝臓内科 Division of Gastroenterology and Hepatology, Jikei University Kashiwa Hospital
    • 小林 正之 KOBAYASHI Masayuki
    • 東京慈恵会医科大学附属柏病院血液・腫瘍内科 Division of Hematology and Oncology, Department of Internal Medicine, Jikei University Kashiwa Hospital

抄録

ヒト培養細胞由来の沈降B型肝炎(HB)ワクチンを当院附属看護専門学校学生(看護学生)と当院職員の集団接種へ新規導入を検討するため, 従来当院で用いてきたHBワクチンと獲得HBs抗体価および副反応につき比較検討を行った.<BR>2000年度のHBワクチンの集団接種を看護学生にはヒト培養細胞由来HBワクチン(M群)を, 職員には従来通り酵母由来組換えHBワクチン(B群)を0, 4, 24週目に筋肉内接種を行った. 3回の接種を完了した看護学生56名(女性, 19~32歳, 平均20.9歳), 職員23名(女性, 21~32歳, 平均23歳) を対象として解析を行った.<BR>最終獲得HBs抗体価を両群間で<100, 100~599, 600~1999, 2000~3999, ≧4000mIU/mLの5層に分けて比較すると, M群では≧4000に50%以上が, B群では<100と100~599に50%以上が分布し, M群がp<0.001で有意に高抗体価であった. 一方, 副反応の発現数と発現率の比較では, 各回の接種毎のアンケート調査で回答が得られたM群のべ168名とB群のべ54名において, 全身症状はM群10名 (6.0%), B群3名 (5.5%) に, 局所症状はM群11名 (6.5%), B群10名 (18.5%) に各々みられ, 局所症状においてB群がp<0.05で有意に高頻度であった.<BR>以上のことから, ヒト培養細胞由来HBワクチンの有用性が示された.

We plan to introduce an adsorbed hepatitis B (HB) vaccine derived from human cell culture for mass inoculation of our hospital personnel and students of the attached school of nursing (student nurses). To assess the effectiveness of the new HB vaccine, the titer of acquired antibody to hepatitis B surface antigen (anti-HBs) and the side effects of the vaccine were compared with those of a conventional HB vaccine that has been used for the same purpose in the past. The student nurses (Group M) and the hospital personnel (Group B) underwent mass inoculation with the HB vaccine in the 2000 academic year, with three intramuscular doses of a human cell culture-derived HB vaccine or a conventional yeast-derived recombinant HB vaccine, respectively, at 0, 4, and 24 weeks. Data were analyzed from those subjects who received all three inoculations, consisting of 56 student nurses (females aged 19 to 32 years; mean age, 20.9 years) and 23 hospital personnel (females aged 21 to 32 years; mean age, 23 years). The final acquired anti-HBs levels were compared between groups by stratifying the recipients into five titer groups (<100, 100-599, 600-1999, 2000-3999, and ≥4000mIU/mL).In Group M, ≥50% of recipients had antibody levels of ≥4000mIU/mL, whereas in Group B, ≥50% of recipients had antibody levels of either <100 or 100-599mIU/mL, revealing a significantly higher antibody response in Group M than in Group B (p<0.001). The number and rate of observed side effects were compared using 168 and 54 completed post-inoculation questionnaires returned by recipients in Groups M and B, respectively. Systemic symptoms developed in 10 subjects (6.0%) in Group M and three subjects (5.5%) in Group B. Local symptoms developed in 11 subjects (6.5%) in Group M and in 10 subjects (18.5%) in Group B, revealing a significantly higher frequency of local symptoms in Group B (p<0.05). These results demonstrate the effectiveness of this human cell culture-derived HB vaccine.

収録刊行物

  • 環境感染  

    環境感染 21(4), 258-262, 2006-12-20 

    Japanese Society of Environmental Infections

参考文献:  16件

参考文献を見るにはログインが必要です。ユーザIDをお持ちでない方は新規登録してください。

各種コード

  • NII論文ID(NAID)
    10021243507
  • NII書誌ID(NCID)
    AN1019475X
  • 本文言語コード
    JPN
  • 資料種別
    ART
  • ISSN
    09183337
  • NDL 記事登録ID
    8641581
  • NDL 雑誌分類
    ZS9(科学技術--医学--病理学・微生物学・寄生虫学・感染・免疫学・血清学・アレルギー)
  • NDL 請求記号
    Z19-3650
  • データ提供元
    CJP書誌  NDL  J-STAGE 
ページトップへ